Oragenics (NYSE:OGEN) Now Covered by StockNews.com

StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a research report sent to investors on Sunday. The brokerage issued a sell rating on the stock.

Oragenics Stock Down 5.5 %

Shares of NYSE OGEN opened at $0.36 on Friday. The stock has a market cap of $4.34 million, a P/E ratio of -0.05 and a beta of 0.43. The firm’s 50-day simple moving average is $0.32 and its 200 day simple moving average is $0.75. Oragenics has a fifty-two week low of $0.25 and a fifty-two week high of $7.74.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.